The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new framework to spur the development of therapies for ultra-rare ...

This deal adds two more siRNA candidates to GSK’s pipeline, which is expanding as the company looks to offset the impact of ...

Beren Therapeutics has received the US (FDA acceptance to review its NDA for adrabetadex, an investigational therapy targeting intracellular cholesterol trafficking for infantile-onset NPC.

AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing ...